The Core Question
When the NewSelf program charges $99.97/month for compounded semaglutide and Ro Body charges $299/month for the same active ingredient, the question is: what explains the difference — and does it matter for patient outcomes? The answer is nuanced and matters for your decision.
| Provider | Sema/Mo | Tirz/Mo | Membership | Dose Upcharge | FDA Warning |
|---|---|---|---|---|---|
| NewSelf (promo) | $99.97 | $144.49 | None | None | Feb 2026 |
| Ro Body | $299 | Brand only | $145/mo | Yes | None |
| Hims & Hers | $299 | No compounded | None | No | None |
| Henry Meds | $297 | Oral only | None | No | None |
⚡ Limited Time: Free Overnight Shipping
NewSelf semaglutide from $99.97/mo — up to 3x cheaper than Ro, Hims, or Henry. Start your free visit today.
✓ All dosages same price · ✓ Full refund if declined · ✓ No membership fees
Why Ro Is 3x the Price
Ro Body's $299 semaglutide plus $145/month membership reflects substantial platform overhead: the Ro brand is a full-service healthcare company with extensive provider networks, a dedicated care app, broad product portfolio, pharmacy operations, and significant brand investment. Ro also focuses on brand-name pharmacy partnerships and has not received a public FDA warning letter. The premium buys regulatory track record, brand trust, and a more integrated health experience — not a meaningfully different medication outcome for most patients.
Hims & Hers: No Tirzepatide, Same Price as Ro
Hims & Hers charges approximately $299/month for compounded semaglutide and does not offer compounded tirzepatide. For patients who want the dual GLP-1/GIP option, Hims is immediately eliminated as an option. For semaglutide-only patients, NewSelf GLP-1 telehealth at $99.97 (confirmed) is substantially cheaper. Hims has a strong consumer brand and no outstanding FDA warning letter — legitimate advantages for those prioritizing regulatory track record over price.
Henry Meds: Oral Focus, Month-to-Month Advantage
Henry Meds at $297/month focuses primarily on oral compounded semaglutide. For patients who prefer not to self-inject, Henry is worth considering. Injectable tirzepatide is not in their standard compounded program. Henry has no public FDA warning letter and offers month-to-month billing with cleaner cancellation terms than NewSelf's program — making it the lower-commitment, lower-regulatory-risk alternative at a premium price.
Is the Premium Worth It?
For most price-sensitive patients who confirm the promotional checkout price and fully understand the 3-month commitment: start a NewSelf GLP-1 plan's value proposition is compelling. The medication contains the same active ingredient. The pharmacy testing protocols are comparable. The physician review is equally individualized. The premium at Ro, Hims, or Henry buys brand trust, regulatory clean record, and (in some cases) integrated digital experience — real benefits, but not clinically superior medication outcomes for most patients.